Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2019 May 17;19(9):560–569. doi: 10.1016/j.clml.2019.05.001

Figure 2.

Figure 2.

Progression free survival outcomes in patients receiving the mCBAD regimens-Kaplan Meier survival curves showing A. Progression free survival (PFS) from the initiation of mCBAD in patients with relapsed refractory multiple myeloma (RRMM) B. PFS in patients with RRMM who underwent subsequent autologous stem cell transplant (ASCT), C. PFS in patients with RRMM who did not undergo ASCT, and D. PFS in patients with newly diagnosed multiple myeloma.